Colobreathe
Author: Sultan Khan
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Colobreathe (colistimethate sodium; Allergan) is a dry powder inhaler formulation of the antibiotic colistimethate sodium that is approved for the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis. Colistimethate belongs to the polymyxin class of antibiotics, which interact with lipopolysaccharide molecules in the outer membrane of Gram-negative bacteria, increasing permeability and leading to cell death. Colobreathe is delivered via the Turbospin inhaler device, which is manufactured by PH&T and allows for a simple and convenient twice-daily administration rather than a lengthy nebulization process.
TABLE OF CONTENTS
4 PRODUCT PROFILES
4 Colobreathe : Cystic fibrosis
LIST OF FIGURES
6 Figure 1: Colobreathe for cystic fibrosis – SWOT analysis
8 Figure 2: Datamonitor Healthcare’s drug assessment summary for Colobreathe in cystic fibrosis
8 Figure 3: Datamonitor Healthcare’s drug assessment summary for Colobreathe in cystic fibrosis
LIST OF TABLES
4 Table 1: Colobreathe drug profile
6 Table 2: Colobreathe pivotal trial data in cystic fibrosis
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
2017 Biomedtracker / Meddevicetracker / Datamonitor Healthcare Post-ESC Rep... 
Sign up to the